{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T03:06:07Z","timestamp":1648868767085},"reference-count":8,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 26-year-old woman was initially diagnosed with stage III classical Hodgkin lymphoma (HL) treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for 6 cycles and relapsed 9 months after completing therapy. She was treated with salvage chemotherapy followed by an autologous transplantation and 1 year of brentuximab vedotin (BV) maintenance therapy. She now presents 1 year later with relapsed disease above and below the diaphragm. What treatment would you recommend for this patient?<\/jats:p>","DOI":"10.1182\/hematology.2019000077","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:18:05Z","timestamp":1575645485000},"page":"249-251","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Evidence-Based Minireview: What is the optimal timing of anti\u2013PD-1 antibodies in relapsed classical Hodgkin lymphoma?"],"prefix":"10.1182","volume":"2019","author":[{"given":"Pamela Blair","family":"Allen","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"23","key":"2019120610120349000_B1","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019120610120349000_B2","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019120610120349000_B3","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"31","key":"2019120610120349000_B4","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019120610120349000_B5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2019120610120349000_B6","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019120610120349000_B7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"issue":"23","key":"2019120610120349000_B8","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/249\/1546074\/hem2019000077c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/249\/1546074\/hem2019000077c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:18:08Z","timestamp":1575645488000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/249\/422590\/EvidenceBased-Minireview-What-is-the-optimal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000077","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}